Meeting
2022 ASCO Genitourinary Cancers Symposium
ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations.
Authors
Yasser Ged
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Yasser Ged , Irina Rifkind , Amber Michalik , Michael Anthony Carducci , Mark Christopher Markowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03786796
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS400)
DOI
10.1200/JCO.2022.40.6_suppl.TPS400
Abstract #
TPS400
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh